Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

References

• Dobrenkov K, Cheung NK. GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol. 2014;41:589-612. doi:10.1053/j.seminoncol.2014.07.003. PMID:25440605.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-34. doi:10.1056/NEJMoa0911123. PMID:20879881.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. MAbs. 2013;5:801-9. doi:10.4161/mabs.25215. PMID:23924804.
   PubMed Web of Science ®Google Scholar
• Siebert N, Eger C, Seidel D, Juttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs. 2016;8:604-16. doi:10.1080/19420862.2015.1130196. PMID:26785755.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S. Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission. J Clin Oncol. 2012;30:3264-70. doi:10.1200/JCO.2011.41.3807. PMID:22869886.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH. Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014;135:2199-205. doi:10.1002/ijc.28851. PMID:24644014.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. OncoImmunology. 2015;4:e1016704; doi:10.1080/2162402X.2015.1016704. PMID:26140243.
   PubMed Web of Science ®Google Scholar
• Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014;74:1047-55. doi:10.1007/s00280-014-2575-9. PMID:25212536.
   PubMed Web of Science ®Google Scholar
• Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32:1445-52. doi:10.1200/JCO.2013.50.4423. PMID:24711551.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. OncoImmunology. 2012;1:477-86. doi:10.4161/onci.19864. PMID:22754766.
   PubMed Web of Science ®Google Scholar
• Basu EM, Kushner B, Modak S, Roberts S,   YF, Tran H, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors. Advances in Neuroblastoma Research meeting. 2014;2:p. 242 [abstract].
   Google Scholar
• Shi B, Derendorf H. Pediatric dosing and body size in biotherapeutics. PHarmaceutics. 2010;2:389-418. doi:10.3390/pharmaceutics2040389. PMID:27721364.
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-67. doi:10.1056/NEJMra035092. PMID:13679531.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit. 2007;29:271-8. doi:10.1097/FTD.0b013e318042d3c4. PMID:17529882.
   PubMed Web of Science ®Google Scholar
• HHS-FDA-CDER. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products - Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2014.
   Google Scholar
• Kovarik JM, Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002;74:966-71. doi:10.1097/00007890-200210150-00011. PMID:12394838.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, Bouw MR. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008;12:447-55. doi:10.1111/j.1399-3046.2007.00830.x. PMID:18466432.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer. 2009;53:978-83. doi:10.1002/pbc.22209. PMID:19637330.
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007;64:278-91. doi:10.1111/j.1365-2125.2007.02914.x. PMID:17506867.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007;44:185-91. doi:10.1097/01.mpg.0000252191.05170.e7. PMID:17255829.
   PubMed Web of Science ®Google Scholar
• Grundy J, Pan WJ, Kugathasan S, Nagpala F, Hilton D, Taylor J, et al. Pharmacokinetics and pharmacodynamics of natalizumab in a phase II study of adolescent patients with Crohn's disease. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. 2005;41:p. 538 [abstract]; doi:10.1097/01.mpg.0000182003.06031.00
   Web of Science ®Google Scholar
• Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol. 2009;27:5102-8. doi:10.1200/JCO.2008.20.8975. PMID:19770383.
   PubMed Web of Science ®Google Scholar
• Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res. 2006;12:6517-22. doi:10.1158/1078-0432.CCR-06-0705. PMID:17065274.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008;26:399-405. doi:10.1200/JCO.2007.11.9230. PMID:18202416.
   PubMed Web of Science ®Google Scholar
• Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833-8. doi:10.1016/j.jpeds.2008.06.011. PMID:18672254.
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44:873-80. doi:10.1177/0091270004267595. PMID:15286091.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res. 2000;6:2653-60. PMID:10914706.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Roque-Navarro L, Lopez-Requena A, Moreno E, Mateo de Acosta C, Perez R, María Vázquez A. Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology. 2007;212:57-70. doi:10.1016/j.imbio.2006.08.005. PMID:17270710.
   PubMed Web of Science ®Google Scholar
• Delgado-Roche L, Brito V, Acosta E, Perez A, Fernandez JR, Hernandez-Matos Y, Griñán T, Soto Y, León OS, Marleau S, et al. Arresting progressive atherosclerosis by immunization with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice. Free Radic Biol Med. 2015;89:557-66. doi:10.1016/j.freeradbiomed.2015.08.027. PMID:26454078.
   PubMed Web of Science ®Google Scholar
• Soto Y, Mesa N, Alfonso Y, Perez A, Batlle F, Grinan T, Pino A, Viera J, Frómeta M, Brito V, et al. Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody. MAbs 2014;6:1340-6. doi:10.4161/mabs.29970. PMID:25517318.
   PubMed Web of Science ®Google Scholar
• Sarduy R, Brito V, Castillo A, Soto Y, Grinan T, Marleau S, Vázquez AM. Dose-dependent induction of an idiotypic cascade by anti-glycosaminoglycan monoclonal antibody in apoE-/- mice: Association with atheroprotection. Front Immunol 2017;8:232; doi:10.3389/fimmu.2017.00232. PMID:28316603.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Canete A, Cheung IY, Ye JN, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 1993;54:499-505. doi:10.1002/ijc.2910540324. PMID:8509225.
   PubMed Web of Science ®Google Scholar